{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000044","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.621971+00:00","generated_at":"2026-06-08T13:57:34.284991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023","bullets":["Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.","Cash, equivalents & short-term investments $140.8M as of Sep 30, 2023.","Top-line 48-week MOMENTUM Phase 2 obesity trial data expected Q4 2023; 391 subjects randomized.","HepTcell Phase 2 CHB top-line results anticipated Q1 2024; ~80 subjects enrolled.","Pemvidutide granted Fast Track for NASH; IMPACT Phase 2b enrollment ongoing; results Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000044","json":"https://secwatch.observer/filing/0001326190-23-000044.json","markdown":"https://secwatch.observer/filing/0001326190-23-000044.md","text":"https://secwatch.observer/filing/0001326190-23-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/0001326190-23-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/alt-20231107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:57:34.284991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d329fb8cd9502920148ee404241173c9a8d3225","claim":"Altimmune, Inc. reported the three months ended September 30, 2023 results: net income $20.7 million, or $0.39 net loss per share, EPS $0.39 net loss per share.","evidence_excerpt":"Net loss for the three months ended September 30, 2023 was $20.7 million, or $0.39 net loss per share, compared to a net loss of $23.5 million, or $0.48 net loss per share, in the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/0001326190-23-000044-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Net income","value":"$20.7 million, or $0.39 net loss per share"},{"label":"EPS","value":"$0.39 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}